Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
704 (USA) · Dr. Tanaka
consented 2013-08-25
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DYSPNOEA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-09-28 (study day 35.0); relationship: NONE
moderate
assessed
Moderate RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-14 (study day -11.0); relationship: NONE
Data queries
No data queries.